{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=13", "query": { "intervention": "Viread", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 522, "total_pages": 53, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T15:42:09.480Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04535544", "title": "A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis D, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Entecavir (ETV) monohydrate", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 52, "start_date": "2020-09-17", "completion_date": "2025-03-05", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 2, "location_summary": "Redwood City, California • Boston, Massachusetts", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04535544" }, { "nct_id": "NCT01855867", "title": "HIV Non-Occupational Post-Exposure Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth H. Mayer, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2013-05", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01855867" }, { "nct_id": "NCT02367807", "title": "PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [ { "name": "Emtricitabine and tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philadelphia Fight", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "MALE", "summary": "18 Years to 30 Years · Male only" }, "enrollment_count": 50, "start_date": "2015-02", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367807" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" }, { "nct_id": "NCT03332095", "title": "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Doravirine (DOR)", "type": "DRUG" }, { "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)", "type": "DRUG" }, { "name": "Antiretroviral (ARV) medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 55, "start_date": "2018-07-02", "completion_date": "2022-05-25", "has_results": true, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 4, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332095" }, { "nct_id": "NCT02979613", "title": "Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "TDF", "type": "DRUG" }, { "name": "TAF Placebo", "type": "DRUG" }, { "name": "TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2016-12-29", "completion_date": "2020-01-30", "has_results": true, "last_update_posted_date": "2020-09-14", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 17, "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02979613" }, { "nct_id": "NCT01198860", "title": "Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "CHRONIC HEPATITIS B" ], "interventions": [ { "name": "CTH Chronic Hepatitis B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nguyen Thi Trieu, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198860" }, { "nct_id": "NCT02016924", "title": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "BR", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "LPV/r", "type": "DRUG" }, { "name": "Third Unboosted Drug", "type": "DRUG" }, { "name": "Cobicistat TOS", "type": "DRUG" }, { "name": "F/TAF TOS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 133, "start_date": "2014-01-16", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 7, "location_summary": "Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02016924" }, { "nct_id": "NCT00414635", "title": "FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Intermitent Dosing", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2006-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414635" }, { "nct_id": "NCT01040091", "title": "Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Emtricitabine (FTC)", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate (TDF)", "type": "DRUG" }, { "name": "Efavirenz (EFV)", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2009-12", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-11-14T15:42:09.480Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040091" } ] }